RenovoRx Inc
RNXT1.210USD
0.000
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
44.22MValor de mercado
PerdaP/L TTM
Mais detalhes de RenovoRx Inc Empresa
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Informações da empresa
Código da empresaRNXT
Nome da EmpresaRenovoRx Inc
Data de listagemAug 17, 2021
CEOMr. Shaun R. Bagai
Número de funcionários10
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 17
Endereço2570 W. El Camino Real, Ste. 320,
CidadeMOUNTAIN VIEW
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94040
Telefone14088002649
Sitehttps://renovorx.com/
Código da empresaRNXT
Data de listagemAug 17, 2021
CEOMr. Shaun R. Bagai
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Dr. Una S. Ryan, Ph.D.
Dr. Una S. Ryan, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Ronald B. (Ron) Kocak, CPA
Mr. Ronald B. (Ron) Kocak, CPA
Principal Financial Officer and Accounting Officer, Vice President, Controller
Principal Financial Officer and Accounting Officer, Vice President, Controller
--
--
Mr. Shaun R. Bagai
Mr. Shaun R. Bagai
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Spiegel, M.D.
Dr. Robert J. (Bob) Spiegel, M.D.
Independent Director
Independent Director
40.98K
--
Ms. Kirsten Angela Macfarlane
Ms. Kirsten Angela Macfarlane
Independent Director
Independent Director
40.98K
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Dr. Laurence J. Marton, M.D.
Dr. Laurence J. Marton, M.D.
Independent Director
Independent Director
--
--
Ms. Leesa Gentry
Ms. Leesa Gentry
Chief Clinical Officer
Chief Clinical Officer
--
--
Dr. Ramtin Agah, M.D.
Dr. Ramtin Agah, M.D.
Chairman of the Board, Co-Founder, Chief Medical Officer
Chairman of the Board, Co-Founder, Chief Medical Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Investidores
Investidores
Proporção
AIGH Capital Management, LLC.
7.09%
AWM Investment Company, Inc.
6.25%
The Vanguard Group, Inc.
3.68%
Agah (Ramtin M.D.)
3.10%
Worth Venture Partners, LLC
2.39%
Other
77.49%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
10.42%
Private Equity
7.09%
Investment Advisor
5.92%
Individual Investor
4.42%
Hedge Fund
3.79%
Bank and Trust
0.27%
Venture Capital
0.06%
Other
68.03%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
51
11.69M
31.97%
+5.32M
2025Q1
52
10.53M
29.46%
+6.73M
2024Q4
39
1.47M
4.14%
-2.25M
2024Q3
38
2.35M
9.16%
-392.19K
2024Q2
40
2.34M
14.23%
-1.80M
2024Q1
36
1.98M
17.38%
-1.99M
2023Q4
40
1.81M
16.91%
-1.93M
2023Q3
39
3.15M
32.01%
-2.10M
2023Q2
36
3.04M
31.03%
-2.11M
2023Q1
36
5.01M
55.46%
+3.39M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
AIGH Capital Management, LLC.
2.59M
7.09%
+2.59M
--
Mar 31, 2025
AWM Investment Company, Inc.
2.29M
6.25%
+2.29M
--
Mar 31, 2025
The Vanguard Group, Inc.
1.35M
3.68%
+1.20M
+851.09%
Mar 31, 2025
Agah (Ramtin M.D.)
1.13M
3.1%
+21.00K
+1.89%
Jun 05, 2025
Worth Venture Partners, LLC
873.61K
2.39%
+873.61K
--
Mar 31, 2025
Alyeska Investment Group, L.P.
688.58K
1.88%
+688.58K
--
Mar 31, 2025
Bleichroeder LP
500.00K
1.37%
+500.00K
--
Mar 31, 2025
Adar1 Capital Management LLC
479.88K
1.31%
+282.63K
+143.29%
Mar 31, 2025
Geode Capital Management, L.L.C.
321.87K
0.88%
+86.13K
+36.53%
Mar 31, 2025
Bagai (Shaun R.)
320.04K
0.88%
+27.50K
+9.40%
Apr 25, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
